TY - JOUR
T1 - Are Environmental Factors for Atopic Eczema in ISAAC Phase Three due to Reverse Causation?
AU - ISAAC Phase Three Study Group
AU - Rutter, Charlotte E.
AU - Silverwood, Richard J.
AU - Williams, Hywel C.
AU - Ellwood, Philippa
AU - Asher, M. I.
AU - Garcia-Marcos, Luis
AU - Strachan, David P.
AU - Pearce, Neil
AU - Langan, Sinéad M.
AU - Aït-Khaled, N.
AU - Anderson, H. R.
AU - Asher, M. I.
AU - Beasley, R.
AU - Björkstén, B.
AU - Brunekreef, B.
AU - Crane, J.
AU - Flohr, C.
AU - Foliaki, S.
AU - Forastiere, F.
AU - Keil, U.
AU - Lai, C. K.W.
AU - Mallol, J.
AU - Mitchell, E. A.
AU - Montefort, S.
AU - Odhiambo, J.
AU - Robertson, C. F.
AU - Stewart, A. W.
AU - von Mutius, E.
AU - Weiland, S. K.
AU - Weinmayr, G.
AU - Wong, G.
AU - Clayton, T. O.
AU - Ellwood, E.
AU - Baena-Cagnani, C. E.
AU - Gómez, M.
AU - Howitt, M. E.
AU - Weyler, J.
AU - Pinto-Vargas, R.
AU - Petrolera de Salud, Caja
AU - Cunha, A. J.D.A.
AU - de Freitas Souza, L.
AU - Kuaban, C.
AU - Ferguson, A.
AU - Rennie, D.
AU - Standring, P.
AU - Aguilar, P.
AU - Chen, Y. Z.
AU - Sharma, S. K.
AU - Moyes, C.
AU - Lee, B. W.
N1 - Funding Information:
We would like to acknowledge and thank the many funding bodies throughout the world that supported the individual ISAAC centers and collaborators and their meetings. In particular, we wish to thank the London School of Hygiene and Tropical Medicine and the United Kingdom Medical Research Council for supporting the work involved in this article. We also wish to thank the Health Research Council of New Zealand, the Asthma and Respiratory Foundation of New Zealand, the Child Health Research Foundation, the Hawke's Bay Medical Research Foundation, the Waikato Medical Research Foundation, Glaxo Wellcome New Zealand, the NZ Lottery Board, and AstraZeneca New Zealand. Glaxo Wellcome International Medical Affairs supported the regional coordination and the ISAAC International Data Centre. CER is funded by the Medical Research Council (grant number MR/N013638/1). SML is funded by a Wellcome Senior Fellowship in Clinical Science (205039/Z/16/Z). This work was partially supported by the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013/ERC Advanced grant agreement number 668954) grant to NP. Without help from all of these organizations, ISAAC would not have given us results from so many countries. We are grateful to the children and parents who willingly participated and cooperated in ISAAC Phase Three, and the coordination and assistance by the school staff is sincerely appreciated. We thank the Phase Three national coordinators, principal investigators, and their colleagues, who helped make ISAAC Phase Three such a success.
Funding Information:
We would like to acknowledge and thank the many funding bodies throughout the world that supported the individual ISAAC centers and collaborators and their meetings. In particular, we wish to thank the London School of Hygiene and Tropical Medicine and the United Kingdom Medical Research Council for supporting the work involved in this article. We also wish to thank the Health Research Council of New Zealand, the Asthma and Respiratory Foundation of New Zealand, the Child Health Research Foundation, the Hawke’s Bay Medical Research Foundation, the Waikato Medical Research Foundation, Glaxo Wellcome New Zealand, the NZ Lottery Board, and AstraZeneca New Zealand. Glaxo Wellcome International Medical Affairs supported the regional coordination and the ISAAC International Data Centre. CER is funded by the Medical Research Council (grant number MR/N013638/1). SML is funded by a Wellcome Senior Fellowship in Clinical Science (205039/Z/16/Z). This work was partially supported by the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013/ERC Advanced grant agreement number 668954) grant to NP. Without help from all of these organizations, ISAAC would not have given us results from so many countries.
Publisher Copyright:
© 2018 The Authors
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Some previously described environmental associations for atopic eczema may be due to reverse causation. We explored the role of reverse causation by comparing individual- and school-level results for multiple atopic eczema risk factors. The International Study of Asthma and Allergies in Childhood (i.e, ISAAC) Phase Three surveyed children in schools (the sampling unit) regarding atopic eczema symptoms and potential risk factors. We assessed the effect of these risk factors on atopic eczema symptoms using mixed-effect logistic regression models, first with individual-level exposure data and second with school-level exposure prevalence. Overall, 546,348 children from 53 countries were included. At ages 6–7 years, the strongest individual-level associations were with current paracetamol use (odds ratio [OR] = 1.45, 95% confidence interval [CI] = 1.37–1.54), which persisted at school-level (OR = 1.55, 95% CI = 1.10–2.21), early-life antibiotics (OR = 1.41, 95% CI = 1.34–1.48), and early-life paracetamol use (OR = 1.28, 95% CI = 1.21–1.36), with the former persisting at the school level, whereas the latter was no longer observed (OR = 1.35, 95% CI = 1.00–1.82 and OR = 0.94, 95% CI = 0.69–1.28, respectively). At ages 13–14 years, the strongest associations at the individual level were with current paracetamol use (OR = 1.57, 95% CI = 1.51–1.63) and open-fire cooking (OR = 1.46, 95% CI = 1.33–1.62); both were stronger at the school level (OR = 2.57, 95% CI = 1.84–3.59 and OR = 2.38, 95% CI = 1.52–3.73, respectively). Association with exposure to heavy traffic (OR = 1.31, 95% CI = 1.27–1.36) also persisted at the school level (OR = 1.40, 95% CI = 1.07–1.82). Most individual- and school-level effects were consistent, tending to exclude reverse causation.
AB - Some previously described environmental associations for atopic eczema may be due to reverse causation. We explored the role of reverse causation by comparing individual- and school-level results for multiple atopic eczema risk factors. The International Study of Asthma and Allergies in Childhood (i.e, ISAAC) Phase Three surveyed children in schools (the sampling unit) regarding atopic eczema symptoms and potential risk factors. We assessed the effect of these risk factors on atopic eczema symptoms using mixed-effect logistic regression models, first with individual-level exposure data and second with school-level exposure prevalence. Overall, 546,348 children from 53 countries were included. At ages 6–7 years, the strongest individual-level associations were with current paracetamol use (odds ratio [OR] = 1.45, 95% confidence interval [CI] = 1.37–1.54), which persisted at school-level (OR = 1.55, 95% CI = 1.10–2.21), early-life antibiotics (OR = 1.41, 95% CI = 1.34–1.48), and early-life paracetamol use (OR = 1.28, 95% CI = 1.21–1.36), with the former persisting at the school level, whereas the latter was no longer observed (OR = 1.35, 95% CI = 1.00–1.82 and OR = 0.94, 95% CI = 0.69–1.28, respectively). At ages 13–14 years, the strongest associations at the individual level were with current paracetamol use (OR = 1.57, 95% CI = 1.51–1.63) and open-fire cooking (OR = 1.46, 95% CI = 1.33–1.62); both were stronger at the school level (OR = 2.57, 95% CI = 1.84–3.59 and OR = 2.38, 95% CI = 1.52–3.73, respectively). Association with exposure to heavy traffic (OR = 1.31, 95% CI = 1.27–1.36) also persisted at the school level (OR = 1.40, 95% CI = 1.07–1.82). Most individual- and school-level effects were consistent, tending to exclude reverse causation.
UR - http://www.scopus.com/inward/record.url?scp=85060476225&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2018.08.035
DO - 10.1016/j.jid.2018.08.035
M3 - Article
C2 - 30521836
AN - SCOPUS:85060476225
SN - 0022-202X
VL - 139
SP - 1023
EP - 1036
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 5
ER -